Spotlighting Sweden's Undiscovered Gems This September 2024
In This Article:
As European inflation nears the central bank's target and economic sentiment shows signs of improvement, Sweden's stock market is poised for potential opportunities. In this environment, identifying stocks with strong fundamentals and growth prospects becomes crucial for investors looking to capitalize on emerging trends.
Top 10 Undiscovered Gems With Strong Fundamentals In Sweden
| Name | Debt To Equity | Revenue Growth | Earnings Growth | Health Rating |
|---|---|---|---|---|
| Softronic | NA | 3.58% | 7.41% | ★★★★★★ |
| Duni | 29.33% | 10.78% | 22.98% | ★★★★★★ |
| Bahnhof | NA | 9.02% | 15.02% | ★★★★★★ |
| AB Traction | NA | 5.38% | 5.19% | ★★★★★★ |
| Firefly | NA | 15.90% | 31.36% | ★★★★★★ |
| Creades | NA | -28.54% | -27.09% | ★★★★★★ |
| AQ Group | 7.30% | 14.89% | 22.26% | ★★★★★★ |
| Byggm?stare Anders J Ahlstr?m Holding | NA | 33.57% | -9.00% | ★★★★★★ |
| Linc | NA | 56.01% | 0.54% | ★★★★★★ |
| Solid F?rs?kringsaktiebolag | NA | 7.64% | 28.44% | ★★★★☆☆ |
Here's a peek at a few of the choices from the screener.
Biotage
Simply Wall St Value Rating: ★★★★★★
Overview: Biotage AB (publ) offers solutions and products for drug discovery and development, analytical testing, and water and environmental testing, with a market cap of SEK15.79 billion.
Operations: Biotage AB (publ) generates revenue primarily from its Healthcare Software segment, which contributed SEK 2.08 billion. The company's net profit margin is %.
Biotage, a Swedish life sciences firm, has shown impressive financial health with earnings growing 16.2% last year, outpacing its industry’s -13%. The company's debt to equity ratio improved from 19.2% to 4% over five years and interest payments are well covered by EBIT at 11.6x coverage. Recent earnings reports indicate sales of SEK 504 million for Q2-2024 compared to SEK 409 million in the previous year, reflecting robust performance and potential for future growth under new CEO Frederic Vanderhaegen starting September 2024.
-
Click to explore a detailed breakdown of our findings in Biotage's health report.
-
Assess Biotage's past performance with our detailed historical performance reports.
engcon
Simply Wall St Value Rating: ★★★★★☆
Overview: engcon AB (publ) designs, produces, and sells excavator tools across various international markets and has a market cap of SEK18.34 billion.
Operations: The company generates revenue primarily from its Construction Machinery & Equipment segment, amounting to SEK 1.54 billion. The net profit margin is notable at 13.5%.
engcon, a notable player in the machinery sector, reported net income of SEK 55 million for Q2 2024, down from SEK 83 million the previous year. Sales also dipped to SEK 450 million from SEK 508 million. Despite these challenges, EBIT covers interest payments by a substantial margin of 20.4x. The company boasts high-quality earnings and a satisfactory net debt to equity ratio of 8.5%. Future growth is anticipated with earnings forecasted to rise by nearly 44% annually.